Neurimmune Holding

About:

Neurimmune develops innovative immunotherapeutics for human diseases.

Website: http://www.neurimmune.com

Twitter/X: neurimmune

Top Investors: Biogen

Description:

Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with high unmet medical needs. With its unique Reverse Translational Medicine™ platform, Neurimmune creates recombinant human-derived monoclonal antibodies with biophysical characteristics closely resembling those occurring in healthy elderly. These antibodies display unique properties such as target selectivity, superior pharmacodynamics and low immunogenicity, resulting in superior risk profiles and excellent efficacy. Neurimmune’s pipeline comprises programs for a broad variety of disease related targets and specific target conformations. These include misfolded, oligomeric, fibrillar or post-translationally modified forms of disease-associated proteins as well as physiological conformations involved in major disease pathways.

Total Funding Amount:

$150M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Schlieren, Zurich, Switzerland

Founded Date:

2006-01-01

Contact Email:

info(AT)neurimmune.com

Founders:

Jan Grimm, Roger M Nitsch

Number of Employees:

51-100

Last Funding Date:

2017-10-25

IPO Status:

Private

Industries:

© 2025 bioDAO.ai